Journal article
Treatment of Refractory Langerhans Cell Histiocytosis (LCH) With a Combination of 2-Chlorodeoxyadenosine and Cytosine Arabinoside
Journal of pediatric hematology/oncology, v 31(1), 53
01 Jan 2009
PMID: 19125089
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The combination of 2-chlorodeoxyadenosine (2-CDA) and cytosine arabino-side (Ara-C) has been shown to be effective ill children with refractory Langerhans cell histiocytosis (LCH) We have treated 5 patients with recurrent LCH with 2-CDA/Ara-C chemotherapy and closely followed immune and hematopoietic function. These patients display a decline in the absolute CD4, CDS. and natural killer cell number, decrease in the CD4/CD8 ratio. Septic events. including pneumocystis Infection were present after most of-the treatment courses (15/21). These data suggest that 2-CDA Ara-C. should be considered in resistant and relapsed pediatric patients with LCH with high-risk multiorgan involvement. Consequent profound prolonged combined immune deficiency and myelosupression should he anticipated.
Metrics
Details
- Title
- Treatment of Refractory Langerhans Cell Histiocytosis (LCH) With a Combination of 2-Chlorodeoxyadenosine and Cytosine Arabinoside
- Creators
- Nataly Apollonsky - College Station Medical CenterJeffrey M. Lipton - Schneider Children's Hospital
- Publication Details
- Journal of pediatric hematology/oncology, v 31(1), 53
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 4
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000262300800013
- Scopus ID
- 2-s2.0-59449086604
- Other Identifier
- 991021448170204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Hematology
- Oncology
- Pediatrics